Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00706719 · ClinicalTrials.gov registry record · Phase 2
To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone
A Phase 2 study, sponsored by Repros Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT00706719 is a Phase 2 study that has completed, run by Repros Therapeutics. The registered enrollment target is 17 participants.
The verdict
NCT00706719, a Phase 2 study, has completed, sponsored by Repros Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
The study was designed to determine if Androxal® would affect sperm parameters (count, concentration, volume) in men with secondary hypogonadism who have been previously treated with topical testosterone.
Interventions
- DRUG 25 mg Androxal
- DRUG Testim 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2008-06 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00706719
The ClinicalTrials.gov registry entry for NCT00706719 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repros Therapeutics, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 25 mg Androxal is the first listed.
NCT00706719 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00706719 about?
NCT00706719 is a clinical study titled "To Evaluate Sperm Parameters in Men With Secondary Hypogonadism Previously Treated With Topical Testosterone". The study was designed to determine if Androxal® would affect sperm parameters (count, concentration, volume) in men with secondary hypogonadism who have been previously treated with topical testosterone.
What is the current status of trial NCT00706719?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2008-06. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00706719?
The interventions under investigation include: 25 mg Androxal (DRUG), Testim 1% (DRUG).
Who is sponsoring clinical trial NCT00706719?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.